Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
暂无分享,去创建一个
T. Powles | M. Dowsett | Jenny C. Chang | A. Makris | D. Allred | C. Osborne | S. Ashley | J. Chang | R. Gregory | S. Ashley | J. Chang
[1] T. Powles,et al. Clinical studies of apoptosis and proliferation in breast cancer. , 1999, Endocrine-related cancer.
[2] D. Tripathy,et al. Tamoxifen for early breast cancer: An overview of the randomised trials , 1999 .
[3] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[4] T. Powles,et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. Mouridsen,et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Willem,et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer , 1994, The Lancet.
[7] T. Powles,et al. The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-beta 1 in metastatic human breast cancer: an immunocytochemical study. , 1994, European journal of cancer.
[8] K. Maclennan,et al. Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. , 1994, European journal of cancer.
[9] T. Fornander,et al. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. , 1993, Journal of the National Cancer Institute.
[10] M. Lindstrom,et al. Tamoxifen-induced increase in the potential doubling time of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry. , 1993, Cancer research.
[11] A. Howell,et al. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. , 1993, British Journal of Cancer.
[12] W. McGuire,et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Tubiana-Hulin,et al. Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy, tumor regression, and short‐term follow‐up , 1992, Cancer.
[14] C. McDonald,et al. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. , 1991, BMJ.
[15] N. Davidson,et al. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. , 1991, Cancer research.
[16] D. DeMets,et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. , 1990, Journal of the National Cancer Institute.
[17] J. Meyer,et al. Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. , 1989, The American journal of pathology.
[18] I. Jackson,et al. Antioestrogens in the management of hormone-dependent cancer. , 1988, Cancer treatment reviews.
[19] W. McGuire,et al. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens , 1988, Cancer.
[20] A. Howell,et al. Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. , 1987, Cancer research.
[21] C. Osborne,et al. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. , 1984, Cancer research.
[22] M. Daidone,et al. Relationship between estrogen receptors and cellular proliferation. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[23] C. Osborne,et al. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. , 1983, Cancer research.
[24] Johannes Gerdes,et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.
[25] C J Wright,et al. Estrogen receptor status in breast cancer. , 1980, Canadian journal of surgery. Journal canadien de chirurgie.
[26] H. Mouridsen,et al. Tamoxifen in advanced breast cancer. , 1978, Cancer treatment reviews.